Compare Stocks: ADCT, VALN, PRME, and CBIO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$1.26 -2.0%	$1.14	$0.78 ▼ $4.98	$161.38M	1.84	1.35 million shs	1.08 million shs
CBIO Crescent Biopharma	$13.99 -1.8%	$17.10	$8.72 ▼ $27.41	$519.59M	1.24	298,047 shs	228,686 shs
PRME Prime Medicine	$2.90 -5.5%	$3.25	$2.67 ▼ $6.94	$526.00M	2.34	2.94 million shs	7.08 million shs
VALN Valneva	$6.14 -1.3%	$6.07	$4.75 ▼ $12.23	$582.63M	1.67	64,226 shs	15,001 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	-2.21%	+21.80%	+24.15%	+24.15%	-63.85%
CBIO Crescent Biopharma	+0.35%	-15.09%	-16.24%	-22.96%	+9.71%
PRME Prime Medicine	-1.92%	-2.23%	-17.25%	-10.50%	-44.78%
VALN Valneva	-2.05%	-5.33%	-8.26%	+19.85%	-39.61%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$1.26 -2.0%	$1.14	$0.78 ▼ $4.98	$161.38M	1.84	1.35 million shs	1.08 million shs
CBIO Crescent Biopharma	$13.99 -1.8%	$17.10	$8.72 ▼ $27.41	$519.59M	1.24	298,047 shs	228,686 shs
PRME Prime Medicine	$2.90 -5.5%	$3.25	$2.67 ▼ $6.94	$526.00M	2.34	2.94 million shs	7.08 million shs
VALN Valneva	$6.14 -1.3%	$6.07	$4.75 ▼ $12.23	$582.63M	1.67	64,226 shs	15,001 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	-2.21%	+21.80%	+24.15%	+24.15%	-63.85%
CBIO Crescent Biopharma	+0.35%	-15.09%	-16.24%	-22.96%	+9.71%
PRME Prime Medicine	-1.92%	-2.23%	-17.25%	-10.50%	-44.78%
VALN Valneva	-2.05%	-5.33%	-8.26%	+19.85%	-39.61%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADCT ADC Therapeutics	2.33	Hold	$5.00	298.41% Upside
CBIO Crescent Biopharma	2.83	Moderate Buy	$29.60	106.46% Upside
PRME Prime Medicine	2.89	Moderate Buy	$7.47	155.46% Upside
VALN Valneva	1.67	Reduce	$9.30	50.73% Upside

Current Analyst Ratings Breakdown

Latest ADCT, VALN, PRME, and CBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/25/2026	PRME Prime Medicine	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
9/25/2026	PRME Prime Medicine	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$7.00
9/14/2026	VALN Valneva	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/14/2026	CBIO Crescent Biopharma	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$27.00
8/31/2026	PRME Prime Medicine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/27/2026	CBIO Crescent Biopharma	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$27.00
8/25/2026	PRME Prime Medicine	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$7.00
8/25/2026	PRME Prime Medicine	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$7.00
8/24/2026	CBIO Crescent Biopharma	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/18/2026	PRME Prime Medicine	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$9.00
8/18/2026	PRME Prime Medicine	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$9.00

(Data available from 9/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADCT ADC Therapeutics	$81.36M	1.97	N/A	N/A	($1.50) per share	-0.84
CBIO Crescent Biopharma	$10.84M	49.12	N/A	N/A	$14.32 per share	1.00
PRME Prime Medicine	$4.63M	114.59	N/A	N/A	$0.67 per share	4.37
VALN Valneva	$197.56M	2.96	N/A	N/A	$1.39 per share	4.44

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADCT ADC Therapeutics	-$142.62M	-$0.66	N/A	N/A	N/A	-121.77%	N/A	-32.74%	11/10/2026 (Estimated)
CBIO Crescent Biopharma	-$153.94M	-$6.72	N/A	N/A	N/A	N/A	-101.50%	-86.86%	11/5/2026 (Estimated)
PRME Prime Medicine	-$201.14M	-$1.06	N/A	N/A	N/A	-4,613.11%	-188.27%	-59.11%	N/A
VALN Valneva	-$130.33M	-$2.11	N/A	14.02	N/A	-110.33%	-153.20%	-39.50%	11/19/2026 (Estimated)

Latest ADCT, VALN, PRME, and CBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	VALN Valneva	-$0.1886	-$0.40	-$0.2114	-$0.38	$44.17 million	$39.37 million
8/13/2026	Q2 2026	ADCT ADC Therapeutics	-$0.2160	-$0.11	+$0.1060	-$0.11	$18.89 million	$19.25 million
8/6/2026	Q2 2026	PRME Prime Medicine	-$0.24	-$0.24	N/A	-$0.24	$4.40 million	$1.15 million
7/30/2026	Q2 2026	CBIO Crescent Biopharma	-$0.7357	-$0.74	-$0.0043	-$0.74	$0.36 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
CBIO Crescent Biopharma	N/A	N/A	N/A	N/A	N/A
PRME Prime Medicine	N/A	N/A	N/A	N/A	N/A
VALN Valneva	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADCT ADC Therapeutics	N/A	3.03	2.97
CBIO Crescent Biopharma	N/A	9.66	9.66
PRME Prime Medicine	N/A	3.05	3.05
VALN Valneva	2.04	2.16	1.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADCT ADC Therapeutics	41.10%
CBIO Crescent Biopharma	75.19%
PRME Prime Medicine	70.37%
VALN Valneva	11.39%

Insider Ownership

Company	Insider Ownership
ADCT ADC Therapeutics	5.10%
CBIO Crescent Biopharma	24.84%
PRME Prime Medicine	16.04%
VALN Valneva	14.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADCT ADC Therapeutics	191	127.67 million	121.16 million	Optionable
CBIO Crescent Biopharma	44	37.14 million	27.92 million	No Data
PRME Prime Medicine	146	181.38 million	152.28 million	N/A
VALN Valneva	674	94.89 million	80.74 million	Not Optionable

ADCT, VALN, PRME, and CBIO Headlines

Recent News About These Companies

Analyzing Valneva (NASDAQ:VALN) and Septerna (NASDAQ:SEPN)

September 24 at 4:00 AM | defenseworld.netD

Football fundraiser collects £2k for Livingston charity Team Jak Foundation

September 22 at 2:37 PM | msn.com

Valneva's Lyme Shot Nears EU Verdict as Pipeline Readouts and Cost Cuts Converge

September 21, 2026 | ad-hoc-news.deA

Pfizer (PFE), Valneva (VALN) Lyme Vaccine Moves to EMA Review Despite Phase 3 Caveat

September 15, 2026 | insidermonkey.com

Valneva Aktie: Umsatz bricht um 33 Prozent ein

September 9, 2026 | boerse-express.comB

Valneva Aktie: Verkauf von Nantes vereinbart

September 6, 2026 | boerse-express.comB

Valneva (NASDAQ:VALN) Trading Up 7.1% - Time to Buy?

September 2, 2026 | marketbeat.com

Valneva (NASDAQ:VALN) Shares Gap Up - Time to Buy?

September 1, 2026 | marketbeat.com

Potential Moderna-style share surge? Takeover candidates Evotec, Valneva and Vidac Pharma in focus — analysts bullish

September 1, 2026 | msn.com

Valneva's Property Sale Buys Breathing Room as Travel-Vaccine Demand Sours

August 30, 2026 | ad-hoc-news.deA

Valneva's High-Wire Act: Can Cost Cuts and a Pivotal EMA Review Bridge the Gap to 2026?

August 29, 2026 | ad-hoc-news.deA

Answers to 3 questions about a potential Lyme vaccine

August 28, 2026 | msn.com

Valneva's Regulatory Tailwind Collides With a Deepening Loss Profile

August 24, 2026 | ad-hoc-news.deA

Valneva's Analyst Divide Widens as EMA Review Puts Statistical Questions in the Spotlight

August 20, 2026 | ad-hoc-news.deA

Valneva (VALN) Q2 2026 Earnings Call Transcript

August 20, 2026 | finance.yahoo.com

EMA validates marketing authorisation application of Pfizer & Valneva’s PF-07307405, a 6-valent OspA-based Lyme disease vaccine

August 17, 2026 | pharmabiz.comP

EMA validates Pfizer and Valneva’s Lyme disease vaccine

August 17, 2026 | msn.com

Pfizer, Valneva Lyme vaccine starts review in Europe

August 15, 2026 | pharmaphorum.comP

Valneva Shares Climb After Lyme Disease Vaccine Receives EMA Application Acceptance

August 15, 2026 | marketwatch.com

Update: Valneva Shares Gain as Lyme Vaccine Candidate Gets EMA Review

August 15, 2026 | finance.yahoo.com

A Lyme disease vaccine may finally be on the way. Why did it take so long?

August 14, 2026 | nationalpost.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADCT, VALN, PRME, and CBIO Company Descriptions

ADC Therapeutics NYSE:ADCT

$1.26 -0.03 (-2.02%)

Closing price 03:59 PM Eastern

Extended Trading

$1.26 0.00 (-0.32%)

As of 04:40 PM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Crescent Biopharma NASDAQ:CBIO

$13.99 -0.25 (-1.76%)

Closing price 04:00 PM Eastern

Extended Trading

$14.17 +0.18 (+1.29%)

As of 04:42 PM Eastern

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

Prime Medicine NASDAQ:PRME

$2.90 -0.17 (-5.54%)

Closing price 04:00 PM Eastern

Extended Trading

$2.94 +0.04 (+1.21%)

As of 05:05 PM Eastern

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. Genetic mutations implicated in disease are diverse and can range from errors of a single base, known as point mutations, to errors that extend beyond a single base, such as insertions, deletions, duplications, or combinations thereof. We believe the ability to alter the human genome at the foundational level may confer the greatest therapeutic impact on human disease. Gene editing, including platforms such as Prime Editing, is a novel technology that is not yet clinically validated for human therapeutic use. Over the last decade, the field of genetic medicine has evolved tremendously, with groundbreaking advances in gene therapy, cell therapy, RNA therapy, and, more recently, gene editing. These technologies represent dramatic advancements for genetic therapies, but lack the versatility to precisely and efficiently correct the diverse range of mutations or DNA alterations implicated in disease. Prime Medicine was co-founded by a world-renowned leader in the field of gene editing, David Liu, Ph.D. Dr. Liu was joined as co-founder by Andrew Anzalone, M.D., Ph.D., who conceived of and developed Prime Editing technology. Drawn by the promise of Prime Editing’s ability to transform the field of gene editing, we have assembled a diverse team that has grown to more than 150 people as of September 30, 2022. There are no current plans for Dr. Liu to be an officer or director of our company following this offering. He is expected to continue to provide consulting services to us pursuant to a consulting agreement, which has a current term that runs through September 2025 and accommodates a previous commitment with respect to Beam Therapeutics Inc., which could result in or may create the appearance of a conflict of interest. He is also expected to retain his position and affiliation with the Broad Institute, Inc., Howard Hughes Medical Institute and Harvard University. On September 20, 2022, we achieved a major milestone as the United States Patent and Trademark Office, or the USPTO, issued U.S. Patent 11,447,770, or the ‘770 Patent, covering methods of using Prime Editors. The Broad Institute, Inc., or Broad Institute, prepared, filed and prosecuted the ‘770 Patent. While Broad Institute is the owner of the ‘770 Patent, it is exclusively licensed to us under the terms of the license agreement with Broad Institute. The ‘770 Patent is the first issued Prime Editing patent in our licensed patent portfolio and we believe it will be instrumental in protecting our Prime Editing platform and pipeline of gene editing programs. We believe our in-licensed and company-owned Prime Editing technology has transformative potential that could change the course of how disease is treated and overcome the challenges associated with current genetic therapies. We in-license our Prime Editing technology pursuant to a license agreement with Broad Institute. In addition, the license agreement grants us certain rights and licenses under certain patent rights Broad Institute owns or controls, including a license to the ‘770 Patent, which covers Prime Editing technology and expires in 2040. The licenses are limited to the field of prevention or treatment of human disease, and most licenses granted to us under the license agreement are further limited to the prevention or treatment of human disease by editing (including modifying or converting) or targeting DNA ex vivo, in vivo, or through xeno transplantation methods, which we refer to as the Prime Broad Field. We were incorporated under the laws of the State of Delaware in September 2019 under the name Prime Medicine, Inc. Our principal executive offices are located at 21 Erie Street, Cambridge, MA.

Valneva NASDAQ:VALN

$6.14 -0.08 (-1.29%)

Closing price 04:00 PM Eastern

Extended Trading

$6.12 -0.02 (-0.33%)

As of 04:10 PM Eastern

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ADCT, VALN, PRME, and CBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ADCT, VALN, PRME, and CBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ADCT, VALN, PRME, and CBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADCT, VALN, PRME, and CBIO Company Descriptions

ADC Therapeutics NYSE:ADCT

Crescent Biopharma NASDAQ:CBIO

Prime Medicine NASDAQ:PRME

Valneva NASDAQ:VALN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ADCT, VALN, PRME, and CBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ADCT, VALN, PRME, and CBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ADCT, VALN, PRME, and CBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADCT, VALN, PRME, and CBIO Company Descriptions

ADC Therapeutics NYSE:ADCT

Crescent Biopharma NASDAQ:CBIO

Prime Medicine NASDAQ:PRME

Valneva NASDAQ:VALN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools